Until December 2013, trastuzumab, licensed for the treatment of patients with Her2-positive early or metastatic breast cancer, was available as a powder for reconstitution before intravenous...
BJN provides nurses with an evidence base for clinical practice and a platform for professional development. It shares the information and advice that is key to unlocking your full potential.
Clinical expertise
Peer-reviewed research
Best practice guidance
CPD support